|
JAMA Network Open |
Analysis of School-Level Vaccination Rates by Race, Ethnicity, and Geography in New York City |
1 |
Yes |
9/19/2025 |
|
JAMA Oncology |
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic |
1 |
Yes |
11/7/2025 |
|
JAMA Network Open |
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US |
1 |
Yes |
10/26/2025 |
|
JAMA Network Open |
Analysis of Substance Use Disorder Treatment Admissions in the US by Sex and Race and Ethnicity Before and During the COVID-19 Pandemic |
1 |
Yes |
9/23/2025 |
|
JAMA Network Open |
Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19 |
1 |
Yes |
11/5/2024 |
|
JAMA Network Open |
Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19 |
1 |
Yes |
11/5/2024 |
|
JAMA Network Open |
Analysis of Vaccination Rates and New COVID-19 Infections by US County, July-August 2021 |
1 |
Yes |
2/11/2025 |
|
JAMA Network Open |
Analysis of Vaccine Effectiveness Against COVID-19 and the Emergence of Delta and Other Variants of Concern in Utah |
1 |
Yes |
1/14/2025 |
|
JAMA Network Open |
Analysis of Vaccine Effectiveness Against COVID-19 and the Emergence of Delta and Other Variants of Concern in Utah |
1 |
Yes |
1/14/2025 |
|
JAMA Network Open |
Analysis of Vaccine Reactions After COVID-19 Vaccine Booster Doses Among Pregnant and Lactating Individuals |
1 |
Yes |
9/19/2025 |
|
Massachusetts Medical Society |
Annual Education Program 2021: Reimagining Health and Equity in a Post-COVID-19 World |
1.5 |
No |
5/5/2024 |
|
American Medical Association |
Annual Prescription Renewal - Save Time and Improve Medication Adherence |
0.5 |
Yes |
4/25/2025 |
|
Louisiana Medical Mutual Insurance Company (LAMMICO) |
Antibiotic Stewardship Strategies for Adult Outpatient Care |
1.0 |
Yes |
8/2/2026 |
|
JAMA |
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses |
1 |
Yes |
8/4/2024 |
|
JAMA |
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection |
1 |
Yes |
1/14/2025 |
|
JAMA Oncology |
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19 |
1 |
Yes |
8/16/2025 |
|
JAMA |
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients |
1 |
Yes |
5/10/2024 |
|
JAMA Oncology |
Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease |
1 |
Yes |
8/19/2024 |
|
JAMA Network Open |
Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults |
1 |
Yes |
8/1/2025 |
|
JAMA |
Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged =60 Years |
1 |
Yes |
11/5/2024 |
